149 related articles for article (PubMed ID: 27378188)
1. Pharmacokinetics, tissue distribution, excretion, and metabolite profiling of PEGylated rFIX (nonacog beta pegol, N9-GP) in rats.
Sternebring O; Christensen JK; Bjørnsdottir I
Eur J Pharm Sci; 2016 Sep; 92():163-72. PubMed ID: 27378188
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
Tiede A; Abdul-Karim F; Carcao M; Persson P; Clausen WHO; Kearney S; Matsushita T; Negrier C; Oldenburg J; Santagostino E; Young G
Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, tissue distribution and excretion of 40kDa PEG and PEGylated rFVIII (N8-GP) in rats.
Bjørnsdottir I; Sternebring O; Kappers WA; Selvig H; Kornø HT; Kristensen JB; Bagger MA
Eur J Pharm Sci; 2016 May; 87():58-68. PubMed ID: 26517963
[TBL] [Abstract][Full Text] [Related]
5. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
[TBL] [Abstract][Full Text] [Related]
6. FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia
Ezban M; Hermit MB; Persson E
Haemophilia; 2019 Jan; 25(1):154-161. PubMed ID: 30664825
[TBL] [Abstract][Full Text] [Related]
7. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
[TBL] [Abstract][Full Text] [Related]
8. Normal Neurodevelopment and Fertility in Juvenile Male Rats Exposed to Polyethylene Glycol Following Dosing With PEGylated rFIX (Nonacog Beta Pegol, N9-GP): Evidence from a 10-Week Repeat-Dose Toxicity Study.
Jensen VFH; Schefe LH; Jacobsen H; Mølck AM; Almholt K; Sjögren I; Dalsgaard CM; Kirk RK; Benie AJ; Petersen BO; Kyhn MS; Overgaard AJ; Bjørnsdottir I; Stannard DR; Offenberg HK; Egecioglu E
Int J Toxicol; 2022 Dec; 41(6):455-475. PubMed ID: 36036386
[TBL] [Abstract][Full Text] [Related]
9. Steady-State Plasma Concentrations of Polyethylene Glycol (PEG) are Reached in Children and Adults During Once-Weekly Prophylactic Treatment with Nonacog Beta Pegol (N9-GP).
Sternebring O; Gabel-Jensen C; Jacobsen H; Benie AJ; Bjørnsdottir I
BioDrugs; 2019 Dec; 33(6):673-681. PubMed ID: 31549312
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction.
Baumann A; Piel I; Hucke F; Sandmann S; Hetzel T; Schwarz T
Eur J Pharm Sci; 2019 Mar; 130():11-20. PubMed ID: 30654111
[TBL] [Abstract][Full Text] [Related]
11. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.
Rosén P; Rosén S; Ezban M; Persson E
J Thromb Haemost; 2016 Jul; 14(7):1420-7. PubMed ID: 27169618
[TBL] [Abstract][Full Text] [Related]
12. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
Oldenburg J; Carcao M; Lentz SR; Mahlangu J; Mancuso ME; Matsushita T; Négrier C; Clausen WHO; Ehrenforth S; Young G
Haemophilia; 2018 Nov; 24(6):911-920. PubMed ID: 30248217
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Safety and Efficacy of Nonacog Beta Pegol (N9-GP) Administered for at Least 5 Years in Previously Treated Children with Hemophilia B.
Carcao M; Kearney S; Lu MY; Taki M; Rubens D; Shen C; Santagostino E
Thromb Haemost; 2020 May; 120(5):737-746. PubMed ID: 32369845
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of recombinant factor IX before and after GlycoPEGylation.
Nielsen FS; Schmidt AS; Kristensen AK; Nielsen AD; Kristensen BK; Palm L
Int J Pharm; 2020 Oct; 588():119654. PubMed ID: 32693290
[TBL] [Abstract][Full Text] [Related]
15. GlycoPEGylated recombinant factor IX for hemophilia B in context.
Santagostino E; Mancuso ME
Drug Des Devel Ther; 2018; 12():2933-2943. PubMed ID: 30254423
[TBL] [Abstract][Full Text] [Related]
16. Factor IX-deficient plasma spiked with N9-GP behaves similarly to N9-GP post-administration clinical samples in N9-GP ELISA and FIX activity assays.
Sørensen MH; Andersen S; Ezban M
Haemophilia; 2015 Nov; 21(6):832-6. PubMed ID: 25929807
[TBL] [Abstract][Full Text] [Related]
17. High variability in Factor IX one-stage assay in samples spiked with nonacog beta pegol among different pairs of reagent/detection system.
Duboscq C; Sueldo E; Rosa C; Zirpoli M; Ceresetto J; Baques A; Arias M
Int J Lab Hematol; 2024 Feb; 46(1):128-134. PubMed ID: 37704365
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic administration of glycoPEGylated factor IX provides protection and joint outcome superior to recombinant factor IX after induced joint bleeding.
Sun J; Livingston EW; Broberg ML; Johansen PB; Ley CD; Knudsen T; Ezban M; Bateman T; Monahan PE; Taves S
J Thromb Haemost; 2019 Aug; 17(8):1240-1246. PubMed ID: 31148392
[TBL] [Abstract][Full Text] [Related]
19. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B.
Negrier C; Knobe K; Tiede A; Giangrande P; Møss J
Blood; 2011 Sep; 118(10):2695-701. PubMed ID: 21555744
[TBL] [Abstract][Full Text] [Related]
20. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.
Østergaard H; Bjelke JR; Hansen L; Petersen LC; Pedersen AA; Elm T; Møller F; Hermit MB; Holm PK; Krogh TN; Petersen JM; Ezban M; Sørensen BB; Andersen MD; Agersø H; Ahmadian H; Balling KW; Christiansen ML; Knobe K; Nichols TC; Bjørn SE; Tranholm M
Blood; 2011 Aug; 118(8):2333-41. PubMed ID: 21700771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
